A precise evaluation of total, free, and bioavailable testosterone levels clarifies how binding proteins like SHBG and albumin influence blood test results.
Medical blood tests for male hormones can feel confusing when a single report lists several different numbers for the same hormone. A patient might see entries for total testosterone, free testosterone, and bioavailable testosterone, each with its own numerical value and reference range.
These entries do not represent different chemical compounds manufactured by the body. Instead, they describe the exact same circulating molecule partitioned across different carrier proteins in the bloodstream. Understanding what each measurement means, how laboratories calculate or measure them, and why their ratios shift provides clarity for anyone reviewing male hormone assessments.
This resource is published strictly for educational and informational purposes. It does not constitute medical advice, formal diagnosis, or personalized treatment recommendations. Blood testing interpretation, hormone evaluation, and clinical decisions must always be conducted under the direct supervision of a licensed healthcare professional who can evaluate your complete medical history, physical symptoms, and repeat laboratory testing.
To understand laboratory readouts, it helps to examine how the endocrine system transports steroid hormones. Testosterone is a hydrophobic steroid molecule, meaning it does not dissolve easily in water or blood plasma.
To travel from the testes and adrenal glands to target tissues throughout the body, testosterone relies on carrier proteins. Once secreted into the vascular system, the vast majority of testosterone molecules quickly bind to these circulating proteins. Only a tiny fraction remains completely free in solution.
Sex hormone-binding globulin is a glycoprotein produced primarily by the liver. It has a high binding affinity for sex steroids, particularly dihydrotestosterone and testosterone.
Because SHBG binds testosterone so tightly, the hormone molecules attached to it do not readily separate under normal physiological conditions. In most adult men, roughly 50 to 60 percent of circulating testosterone is bound to SHBG. This fraction serves as a circulating reservoir, protecting the hormone from rapid metabolic breakdown and clearance by the liver.
Albumin is the most abundant protein in human blood plasma. Unlike SHBG, albumin binds testosterone with relatively low affinity, often described as a loose or weak bond.
Because this chemical bond is weak, testosterone molecules attached to albumin can dissociate rapidly as blood flows through capillary beds in target tissues. In typical profiles, approximately 40 to 50 percent of circulating testosterone is bound to albumin. Smaller amounts, usually comprising less than one percent, may also associate with minor proteins such as corticosteroid-binding globulin and orosomucoid.
The remaining portion of circulating hormone is unbound, known as free testosterone. In healthy adult men, free testosterone generally accounts for roughly one to four percent of total circulating levels.
These proportions are biological estimates rather than fixed mathematical rules. Individual distributions vary depending on age, nutritional status, genetics, and underlying health conditions.
Understanding these transport mechanisms is essential when reviewing the fundamentals of male hormonal health. When a blood test is performed, the laboratory is evaluating how the hormone is distributed across these specific carrier states.
Laboratories report hormone status using three primary metrics. Each metric answers a distinct physiological question about circulating hormone concentrations.
Total testosterone represents the absolute quantity of testosterone in a given volume of blood plasma or serum. It sums together every fraction, including testosterone bound tightly to SHBG, testosterone bound loosely to albumin, and the free unbound hormone.
Total testosterone is the standard initial biomarker used by clinical guidelines to assess gonadal function. However, total testosterone does not reveal how the hormone is partitioned among transport proteins. A man with very high SHBG and a man with very low SHBG could have identical total testosterone concentrations, yet possess dramatically different amounts of unbound hormone.
Free testosterone measures only the unbound molecules floating independently in blood plasma. Because these molecules are unencumbered by carrier proteins, they are immediately capable of crossing capillary membranes and diffusing into target cells.
According to the classical free-hormone hypothesis, only unbound molecules are readily available to interact with intracellular androgen receptors. While modern endocrinology recognizes that this model simplifies complex tissue-level dynamics, measuring free testosterone remains a critical diagnostic step when binding protein concentrations are atypical.
Bioavailable testosterone refers to the combined sum of free testosterone and albumin-bound testosterone. It is essentially the non-SHBG-bound fraction of circulating hormone.
The concept of bioavailable testosterone is rooted in vascular kinetics. Because the bond between testosterone and albumin is weak, the hormone can detach within the transit time of blood passing through capillary beds.
Therefore, physiological models treat albumin-bound testosterone as functionally available to tissues alongside free testosterone. Bioavailable testosterone reflects this easily accessible pool, separating it from the tightly locked SHBG-bound reserve.
Because SHBG binds more than half of all circulating testosterone, shifts in SHBG concentration directly alter the relationship between total and free testosterone. When SHBG levels change, total testosterone can become misleading if interpreted in isolation.
When circulating SHBG drops, the blood has fewer high-affinity binding sites available. As a result, total testosterone concentrations decrease because the overall vascular storage capacity is reduced, even while the production of free testosterone remains stable.
Clinical research and endocrine guidelines identify several conditions commonly associated with lower SHBG concentrations:
In a man with obesity, a total testosterone reading might fall into what appears to be a hypogonadal range. Yet because his SHBG is low, his free testosterone concentration may sit comfortably within normal limits.
Interpreting his total testosterone without checking his SHBG or free testosterone could lead to an inaccurate conclusion. Exploring these metabolic connections is a vital component of evaluating low testosterone symptoms in clinical practice.
Conversely, when SHBG levels rise, the blood contains an expanded pool of high-affinity binding sites. More testosterone becomes tightly bound to protein carriers, which can keep total testosterone elevated even as the free fraction declines.
Conditions and factors known to elevate SHBG concentrations include:
An older male might receive a total testosterone result of 450 ng/dL, which appears entirely adequate on a standard laboratory reference interval. However, if his SHBG is significantly elevated due to age, his free testosterone might be well below normal reference thresholds.
Without measuring free testosterone or calculating the non-SHBG fraction, underlying androgen deficiency could be missed.
The value printed on a laboratory report depends heavily on the analytical method used to measure it. Clinicians and researchers distinguish carefully between direct physical assays and mathematical calculations.
Total testosterone is determined using serum assays. Modern clinical laboratories typically use one of two main approaches:
The Endocrine Society highlights that assay variability can be substantial. In one documented quality-control trial, 1,133 laboratories tested the exact same blood sample from a hypogonadal individual using 14 different commercial assays. The reported results spanned from 45 ng/dL to 365 ng/dL, illustrating why assay standardization is crucial for borderline results.
The gold standard reference method for measuring free testosterone is equilibrium dialysis. In this procedure, serum is placed into a chamber separated from an assay buffer by a semipermeable membrane.
The pores in the membrane allow small, unbound testosterone molecules to pass freely while blocking larger proteins like SHBG and albumin. Once the unbound molecules achieve chemical equilibrium across the membrane, the concentration of testosterone in the buffer is directly quantified.
While equilibrium dialysis is biologically accurate, it is technically demanding, time-consuming, and expensive. Consequently, it is primarily performed by specialized reference laboratories.
Because equilibrium dialysis is not universally available, many clinicians rely on calculated free testosterone. These mathematical algorithms estimate the unbound fraction using three blood measurements: total testosterone, SHBG, and albumin.
The most widely accepted equations, such as the Vermeulen formula and the empirical Mazer model, use known chemical dissociation constants between testosterone and its carrier proteins. When accurate inputs are provided via reliable total testosterone and SHBG assays, calculated free testosterone correlates closely with equilibrium dialysis.
However, calculated free testosterone remains an estimate. It assumes standard binding constants that might not apply identically to every individual, particularly during acute illness or severe metabolic disruption.
Some commercial laboratories offer a low-cost test known as a direct analog free testosterone immunoassay. This test uses a labeled testosterone analog designed not to bind to SHBG, attempting to quantify free testosterone in a single step.
Every major clinical endocrine body, including the Endocrine Society, explicitly advises against using direct analog immunoassays. Extensive independent research shows that these assays are structurally inaccurate.
They often reflect total testosterone and SHBG binding unpredictably rather than measuring true unbound hormone. Patients reviewing their testosterone laboratory testing guides should verify that their free testosterone was determined by equilibrium dialysis or validated calculation, not an analog immunoassay.
Bioavailable testosterone can be measured physically using ammonium sulfate precipitation. In this assay, ammonium sulfate is added to serum to precipitate and remove the SHBG-bound fraction. The remaining supernatant, containing free and albumin-bound testosterone, is then measured.
Alternatively, bioavailable testosterone can be calculated using the same binding-equilibrium equations used for free testosterone. As with free hormone metrics, calculated bioavailable testosterone depends directly on the accuracy of the underlying total testosterone, SHBG, and albumin inputs.
While blood tests clearly divide testosterone into total, free, and bioavailable fractions, interpreting how these numbers correspond to cellular biological activity involves clinical nuance.
Leading medical organizations provide clear frameworks for diagnosing testosterone deficiency:
Guidelines do not mandate free testosterone testing for every patient. Instead, clinical organizations recommend evaluating free or bioavailable testosterone in specific clinical contexts:
Conversely, if total testosterone is severely suppressed, such as below 150 ng/dL, free testosterone is almost universally low. In such extreme scenarios, measuring free fractions rarely alters the diagnostic conclusion.
The premise that only free or bioavailable testosterone exerts biological effects is an important physiological model, but it remains an active area of scientific study.
Some researchers point out that the free hormone hypothesis oversimplifies how steroids interact with tissues. Evidence suggests that certain cells express megalin, an endocytic receptor capable of internalizing SHBG-bound steroid complexes directly.
Furthermore, local tissue enzymes can convert circulating precursors into active androgens within target organs, a process known as intracrinology. Because tissue-level androgen action cannot be measured directly in routine clinical settings, circulating total, free, and bioavailable numbers remain our best practical proxies, even while biological complexity continues to be investigated.
Interpreting laboratory numbers requires looking at the entire patient rather than analyzing isolated data points on a screen. Clinicians use structured interpretation patterns to avoid common diagnostic errors.
A frequent challenge occurs when a patient's total testosterone sits between 250 and 350 ng/dL. In this grey zone, calculating free testosterone or measuring it via equilibrium dialysis provides crucial clarity.
If free testosterone is well preserved, the borderline total number may simply reflect lower SHBG without an underlying failure of hormone production. If free testosterone is distinctly suppressed alongside clinical symptoms, the clinical picture aligns more closely with genuine androgen deficiency.
Unlike total testosterone, which has achieved partial standardization through CDC programs, free testosterone lacks a universally harmonized reference range. Reference intervals for free testosterone vary significantly depending on the laboratory, the analytical platform, and the specific calculation formula used.
A calculated free testosterone value of 7.0 ng/dL might fall below the lower limit at one commercial laboratory but sit within normal parameters at another. Clinicians must interpret free testosterone results against the specific reference interval established for that exact testing method. Comparing numerical free testosterone values across different laboratories without referencing their distinct intervals leads to significant confusion.
Testosterone never operates in a vacuum. A comprehensive hormonal evaluation frequently incorporates additional biomarkers to establish the underlying cause of an abnormal result:
Integrating these metrics enables healthcare providers to distinguish between lifestyle-induced shifts, systemic illness, and primary endocrine disorders. Those researching medical interventions can find broader context in our analysis of testosterone replacement therapy research.
Examining hypothetical patient scenarios helps illustrate how total, free, and bioavailable testosterone measurements behave in different clinical environments.
A 42-year-old man presents with general fatigue, elevated body mass index, and mild insulin resistance. His initial fasting blood panel reveals a total testosterone level of 240 ng/dL, which flags as low on the laboratory report.
Further testing reveals his SHBG is 14 nmol/L, well below standard reference levels. Because his binding protein capacity is compressed, his calculated free testosterone and bioavailable testosterone are both comfortably within the normal range.
Data from large-scale studies, including the European Male Aging Study, demonstrate that men with low total testosterone driven solely by low SHBG do not exhibit the same physical and sexual symptoms as men with truly deficient free testosterone.
In this pattern, addressing underlying metabolic factors, nutrition, and physical activity often restores SHBG levels and raises total testosterone without requiring endocrine medical therapies.
A 58-year-old man reports a progressive decline in physical stamina and sexual function. His total testosterone is measured at 480 ng/dL, leading him to believe his hormones are functioning normally.
However, an extended evaluation shows his SHBG concentration is 68 nmol/L, reflecting age-related increases in liver globulin production. Because so much of his circulating hormone is tightly bound to SHBG, his equilibrium dialysis free testosterone is distinctly suppressed below the reference minimum.
In this scenario, relying strictly on total testosterone obscured an underlying deficiency in circulating active hormone. Assessing the free fraction provided the missing clinical insight necessary to understand his symptoms.
A 35-year-old man purchases a direct-to-consumer hormone testing kit. The report lists his total testosterone as 520 ng/dL, but flags his free testosterone as severely low, utilizing a direct analog immunoassay.
Concerned by the result, he reviews the findings with an endocrinologist, who recognizes the limitations of direct analog technology. The physician orders a repeat fasting panel evaluated by LC-MS/MS total testosterone, SHBG, and equilibrium dialysis.
The repeat testing reveals normal SHBG and a free testosterone level well within the 50th percentile. The initial alarming result was an analytical artifact stemming from an inaccurate immunoassay methodology.
When discussing hormone blood panels with a qualified medical provider, asking structured, informed questions helps ensure an accurate evaluation. Consider discussing the following points:
These questions focus the conversation on clinical accuracy, rigorous testing standards, and comprehensive diagnostic principles rather than isolated numbers. For more details on diagnostic standards, visit our overview of hormone testing and biomarker analysis.
Yes. When SHBG concentrations are low, as commonly seen in obesity or insulin resistance, the blood has fewer high-affinity protein carriers. Total testosterone drops because the vascular reservoir is smaller, but the unattached free testosterone fraction can remain normal and functional.
Testosterone production follows a distinct circadian rhythm in adult men, reaching its highest concentrations between 7:00 AM and 10:00 AM. In the afternoon and evening, levels can drop significantly. Standard diagnostic thresholds are established exclusively against morning reference populations.
No. Free testosterone refers solely to unbound hormone molecules floating freely in plasma. Bioavailable testosterone combines free testosterone with the loosely bound albumin fraction, representing the total non-SHBG-bound pool.
Different laboratories use different mathematical equations, such as the Vermeulen, Sodergard, or Mazer formulas. Furthermore, each laboratory establishes its own reference intervals based on its analytical equipment and reference populations. A calculated number must always be interpreted against the specific reference range provided on that report.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
